Cantabria Labs

Cantabria Labs is a Spanish dermatological company based in Madrid that develops skincare and sun-protection products sold mainly through pharmacies. It is best known as the maker of Heliocare, a sun-protection range built around Fernblock, a plant-derived ingredient the company patented in the mid-1990s. Cantabria Labs is the parent of a portfolio of dermo-cosmetic brands and describes itself as a leader in dermatological prescriptions in Spain, Italy and Portugal [2].

The company traces its present form to 1994, when it acquired a full stake in IFC (Industrial Farmacéutica Cantabria), then a small family-run laboratory in the northern Spanish region of Cantabria [3]. Some third-party sources give an earlier date of 1989 [8]; the company's own history page treats 1994 as the start of the business under its new ownership, with 1989 most plausibly marking the founding of the predecessor IFC laboratory. The group adopted the name Cantabria Labs in 2018 [3]; earlier it operated under the IFC name.

The defining moment in the company's account is not the acquisition itself but what followed. In 1995, working with Harvard University, it reported the discovery of an oral approach to sun protection and patented Fernblock, a standardised extract of Polypodium leucotomos [3]. According to a dermatologist-curated editorial, the fern is native to Central America and was first valued for its skin-soothing properties by the Chorotega people of Honduras; the same piece credits the ingredient's development to a collaboration with Harvard Medical School and the dermatologist Thomas Fitzpatrick [8]. The 1995 work also produced AM3, a second patented technology from the same period.

Founders are not named in the company's published material. Susana Rodríguez Navarro was appointed chief executive in 2018, the year the Cantabria Labs name was adopted [3].

From a single laboratory the company expanded across southern Europe and beyond. It opened an export department in 2001 and founded an Italian subsidiary with Difa Cooper in 2003. In 2006 it acquired the RetinSphere patent technology, used in products for skin ageing and acne [3], and through the following years it added rights covering hair loss, hyperpigmentation and photoageing.

Academic partnerships became a recurring theme. The company established a Health and Skin Chair with the University of Alcalá in 2014, and in 2017 it signed its first alliance with the Massachusetts Institute of Technology, an agreement it renewed in 2024. The same period saw further international expansion, with subsidiaries founded in Mexico and China in 2017.

More recent milestones include the launch of the Skin Resist line and the creation of the Cantabria Labs Foundation in 2024, and the introduction of new proprietary technologies, including Aspa-Fernblock and Retinduo, in 2025.

Cantabria Labs operates as the parent of several specialised brands, each aimed at a particular skin concern. Alongside Heliocare for sun protection, the portfolio includes Endocare for anti-ageing, Biretix for acne-prone skin, Neoretin for hyperpigmentation, Iraltone for hair care, and Skin Resist for sensitive skin, together with Inmunoferon and the immune-support and supplement lines. A sun-protection brand, Aktuva, was launched in 2026 [3]. The company's parent status is not the result of a single acquisition; the foundational corporate transaction was its 1994 purchase of IFC.

The company positions itself at the intersection of pharmacy and cosmetics, a category often called dermo-cosmetics. Its stated vision is to become "a world leader in dermatology and dermocosmetics," and it lists innovation, entrepreneurship and a sense of community as its core values [4]. The corporate tagline is "Science that cares" [1]. In keeping with that positioning, its products are distributed largely through pharmacies and dermatological channels rather than mass retail, and the group describes a presence in more than 85 countries.

Research is central to how Cantabria Labs presents itself, and much of its public material is organised around named, trademarked technologies rather than individual products. Fernblock remains the most prominent: the company describes it as a patented technology of natural origin that "protects, neutralises and repairs" across sun-protection levels [6]. A dermoi editorial states that Heliocare is supported by more than fifty scientific publications and used by dermatologists in some sixty countries [8].

Beyond Fernblock, the company's published roster of proprietary technologies includes RetinSphere and Retinduo (both combining retinoids), Edafence (an anti-pollution patent introduced in 2017), the SCA Growth Factor, and Aquammunist, among others. Hero ingredients such as these recur across the brand portfolio, linking the otherwise separate product lines to a shared body of in-house research.

Cantabria Labs operates an eco-sustainable production centre at La Concha, in Cantabria, which it inaugurated in 2019. The facility draws on a natural mineral-rich thermal spring and uses geothermal energy from it for power [7]. The company frames environmental responsibility as part of its broader commitment to health, though it publishes no quantified targets, and no environmental certifications are listed on its corporate site.

In 2023 the company presented two joint ventures with public figures: Toty, with the actor Sofía Vergara, and NDL Pro-Health, with the tennis player Rafael Nadal [3]. An editorial feature in dermoi described Cantabria Labs as a pharmaceutical company that grew into a global leader in dermatology. No formal industry awards are recorded in the available sources.

Cantabria Labs is active. Its public history records a continuous stream of product and technology launches, including the new technologies introduced in 2025 and the launch of the Aktuva brand in 2026. It remains headquartered in Madrid, with laboratories in Santander and Madrid and international subsidiaries across Europe, the Americas and Asia.